GlassScriptPhysician profile
Shyam Padmanabhan
NPI 1013224609
$9,930.35
in general payments reported to CMS, 2019-2025
26 companies · $995 in 2025
The $995 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,113 · 2020: $592 · 2021: $804 · 2022: $3,136 · 2023: $1,711 · 2024: $579 · 2025: $995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,891 · Travel and Lodging: $1,394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,891.45 |
| Travel and Lodging | $1,393.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,510.93 | 2021-2025 | Corevalve Evolut R, Onyx Frontier, Linq II |
| Boston Scientific Corporation | $3,118.58 | 2019-2023 | Watchman Access System |
| Edwards Lifesciences Corporation | $713.44 | 2022-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Medtronic Vascular, INC. | $499.61 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $270.79 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $225.18 | 2019-2022 | |
| Abbott Laboratories | $224.38 | 2019-2024 | Gallant, Cardiomems |
| Novartis Pharmaceuticals Corporation | $189.00 | 2019-2025 | |
| Pfizer INC. | $175.20 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $169.11 | 2021-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $155.57 | 2019-2025 | Eliquis, Camzyos |
| Amgen INC. | $144.85 | 2019-2025 | Repatha, Repatha |
| Abiomed | $135.20 | 2023-2025 | Impella |
| Cardiovascular Systems INC. | $67.47 | 2019 | |
| Esperion Therapeutics, INC. | $53.41 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $39.90 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $37.78 | 2019-2020 | |
| Cordis US Corp. | $31.62 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.53 | 2024 | Jardiance |
| Portola Pharmaceuticals, LLC | $24.88 | 2019 | |
| Biosense Webster, INC. | $21.19 | 2023 | Carto 3 |
| Kiniksa Pharmaceuticals International, Plc | $20.22 | 2024 | Arcalyst |
| Cleerly, INC. | $19.39 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Janssen Pharmaceuticals, INC | $19.15 | 2019 | |
| Amarin Pharma, INC. | $17.71 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $14.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shyam Padmanabhan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.